ERIS Lifesciences Ltd (ERIS) — shareholding pattern, promoter holding, financials and share price
About ERIS Lifesciences Ltd (ERIS)
ERIS Lifesciences Ltd operates in the Pharmaceuticals industry, within the Healthcare sector. It trades on the NSE as ERIS and on the BSE under scrip code 540596. Its ISIN is INE406M01024.
ERIS Lifesciences Ltd is engaged in the business of manufacture and marketing of pharmaceutical products. [1]
Eris Lifesciences is an Indian branded formulations company focused on chronic and specialist therapies with expanding sterile injectables and biologics capabilities; it develops, manufactures and commercializes products across cardiology, diabetes, dermatology and other specialty areas and now owns EU‑GMP capable biologics and sterile injectable assets after multiple strategic acquisitions.
The Domestic Branded Formulations (DBF) segment delivered steady growth (Q3 DBF revenue Rs.696 crore, +10% YoY) with strong profitability (Q3 DBF EBITDA margin ~36.5% and 9M margin ~37.1%), and management expects FY26 DBF growth of ~12% and Q4 to reflect the full benefit of recent price increases.
Listed peers in Pharmaceuticals: Granules India Ltd, Pfizer Ltd, Astrazeneca Pharma India Ltd, Caplin Point Laboratories Ltd, OneSource Specialty Pharma Ltd, Natco Pharma Ltd.
Valuation & Returns
10 Jul 2026At ₹1,431 a share on 10 Jul 2026, ERIS Lifesciences Ltd (ERIS) was valued at a price-to-earnings ratio of 30.63x against an industry P/E of 36.41x and a price-to-book of 6.95x on a book value of ₹205.97 per share as of Mar 2025. Solomo computes return on equity of 22.68% and return on capital employed of 15.59% from filed results. Earnings ratios use consolidated results for the twelve months Jun 2025 to Mar 2026.
- P/E
- 30.63x
- Industry P/E
- 36.41x
- P/B
- 6.95x
- EPS (TTM)
- ₹46.72
- Book value / share
- ₹205.97
- ROE
- 22.68%
- ROCE
- 15.59%
- ROA
- 9.21%
- Debt / equity
- 0.87x
- Dividend yield
- 0.5%
- EBITDA margin
- 35.66%
- 52-week range
- ₹1,237.9 – ₹1,887.65
Ratios are computed from filed results and the last recorded price. Not investment advice.
Financial Performance
Mar 2026In the year ended Mar 2026, ERIS Lifesciences Ltd (ERIS) reported revenue of ₹3,129 crore, net profit of ₹648 crore and earnings per share of ₹44.72. That compares with revenue of ₹2,894 crore and net profit of ₹375 crore in Mar 2025. Figures are consolidated, as filed with the exchanges.
In the quarter ended Mar 2026, revenue was ₹757 crore and net profit ₹279 crore (consolidated).
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue (₹ cr) | 1,347 | 1,685 | 2,009 | 2,894 | 3,129 |
| Net profit (₹ cr) | 406 | 374 | 397 | 375 | 648 |
| EPS (₹) | 29.88 | 28.1 | 28.82 | 25.84 | 44.72 |
| Measure | 10Y | 5Y | 3Y | 1Y |
|---|---|---|---|---|
| Sales growth | 11.78% | 10.72% | 11.78% | 41.45% |
| Profit growth | -4.37% | -23.29% | -42.97% | -5.65% |
| Stock price CAGR | - | 14% | 27% | -16% |
Ownership Summary
Jun 2026As of Jun 2026, promoters hold 54.14% of ERIS Lifesciences Ltd (ERIS) (up 0.22 pp QoQ), foreign institutional investors (FII) hold 5.75% and domestic institutional investors (DII) hold 20.72%. Promoters have pledged 16.9% of their holding. Market capitalisation was ₹19,831 crore on 10 Jul 2026. Shareholding is filed quarterly with BSE and NSE; Solomo carries every filing back to Jun 2017.
Largest disclosed public shareholders in Jun 2026: Lilac Investments Limited 8.63%, Hdfc Small Cap Fund 8.33%, Franklin India Small Cap Fund 4.29%, Hetal Rasiklal Shah 2.12%, Bhikhalal Chimanlal Shah 1.93%, Naishadh Vikram Shah 1.66%. Only stakes above the 1% disclosure threshold are named in filings.
| Quarter | Promoter | Pledged | FII | DII | Public |
|---|---|---|---|---|---|
| Jun 2026 | 54.14% | 16.9% | 5.75% | 20.72% | 45.86% |
| Mar 2026 | 53.92% | 16.9% | 6.39% | 20.35% | 46.08% |
| Dec 2025 | 54.85% | 16.9% | 6.85% | 20.32% | 45.15% |
| Sep 2025 | 54.85% | 16.9% | 7.21% | 19.36% | 45.15% |
| Jun 2025 | 54.83% | 16.9% | 8.4% | 18.17% | 45.17% |
| Mar 2025 | 54.85% | 18.5% | 8.43% | 18.07% | 45.15% |
| Dec 2024 | 54.86% | 18.5% | 8.35% | 18.06% | 45.14% |
| Sep 2024 | 54.87% | 18.5% | 8.01% | 18.64% | 45.13% |